Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls (original) (raw)

• Blennow K, Fredman P, Wallin A et al (1993) Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18–88 years of age. Eur Neurol 33:129–133
  Article PubMed CAS Google Scholar
• Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26:231–245. doi:10.1007/BF02815140
  Article PubMed CAS Google Scholar
• Castellano JM, Kim J, Stewart FR et al (2011) Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 3:89ra57. doi:10.1126/scitranslmed.3002156
• Corder EH, Saunders AM, Risch NJ et al (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7:180–184
  Article PubMed CAS Google Scholar
• Cramer PE, Cirrito JR, Wesson DW et al (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335:1503–1506. doi:10.1126/science.1217697
  Article PubMed Central PubMed CAS Google Scholar
• Cruchaga C, Kauwe JS, Nowotny P et al (2012) Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer’s disease. Hum Mol Genet 21:4558–4571. doi:10.1093/hmg/dds296
  Article PubMed Central PubMed CAS Google Scholar
• Darreh-Shori T, Forsberg A, Modiri N et al (2011) Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer’s disease in the brain in vivo. Neurobiol Aging 32(2320):e2315–e2332. doi:10.1016/j.neurobiolaging.2010.04.028
  Google Scholar
• Fagan AM, Mintun MA, Mach RH et al (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59:512–519. doi:10.1002/ana.20730
  Article PubMed CAS Google Scholar
• Farrer LA, Cupples LA, Haines JL et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA 278:1349–1356
  Article PubMed CAS Google Scholar
• Gregg RE, Zech LA, Schaefer EJ, Stark D, Wilson D, Brewer HB Jr (1986) Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest 78:815–821. doi:10.1172/JCI112645
  Article PubMed Central PubMed CAS Google Scholar
• Gupta VB, Laws SM, Villemagne VL et al (2011) Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 76:1091–1098. doi:10.1212/WNL.0b013e318211c352
  Article PubMed CAS Google Scholar
• Hatters DM, Peters-Libeu CA, Weisgraber KH (2006) Apolipoprotein E structure: insights into function. Trends Biochem Sci 31:445–454. doi:10.1016/j.tibs.2006.06.008
  Article PubMed CAS Google Scholar
• Hegele RA (2009) Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 10:109–121. doi:10.1038/nrg2481
  Article PubMed CAS Google Scholar
• Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545–548
  PubMed CAS Google Scholar
• Hudry E, Dashkoff J, Roe AD et al (2013) Gene transfer of human apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med 5:212ra161. doi:10.1126/scitranslmed.3007000
• Kok E, Haikonen S, Luoto T et al (2009) Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 65:650–657. doi:10.1002/ana.21696
  Article PubMed CAS Google Scholar
• LaClair KD, Manaye KF, Lee DL et al (2013) Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol Neurodegener 8:18. doi:10.1186/1750-1326-8-18
  Article PubMed Central PubMed CAS Google Scholar
• Lahoz C, Schaefer EJ, Cupples LA et al (2001) Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 154:529–537. doi:10.1016/S0021-9150(00)00570-0
  Article PubMed CAS Google Scholar
• Linton MF, Gish R, Hubl ST et al (1991) Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest 88:270–281. doi:10.1172/JCI115288
  Article PubMed Central PubMed CAS Google Scholar
• Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106–118. doi:10.1038/nrneurol.2012.263
  Article PubMed Central PubMed CAS Google Scholar
• Liu M, Kuhel DG, Shen L, Hui DY, Woods SC (2012) Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice. Am J Physiol Regul Integr Comp Physiol 303:R903–R908. doi:10.1152/ajpregu.00219.2012
  Article PubMed Central PubMed CAS Google Scholar
• Ly S, Altman R, Petrlova J et al (2013) Binding of apolipoprotein E inhibits the oligomer growth of amyloid-beta peptide in solution as determined by fluorescence cross-correlation spectroscopy. J Biol Chem 288:11628–11635. doi:10.1074/jbc.M112.411900
  Article PubMed CAS Google Scholar
• Mahley RW, Rall SC Jr (2000) Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1:507–537. doi:10.1146/annurev.genom.1.1.507
  Google Scholar
• Mahley RW, Weisgraber KH, Huang Y (2009) Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS. J Lipid Res 50(Suppl):S183–S188. doi:10.1194/jlr.R800069-JLR200
  PubMed Central PubMed Google Scholar
• Martinez-Morillo E, Nielsen HM, Batruch I et al (2014) Assessment of Peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein e isoforms. J Proteome Res 13:1077–1087. doi:10.1021/pr401060x
  Article PubMed CAS Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944
  Article PubMed CAS Google Scholar
• McKhann G (1987) Diagnostics and statistical manual of mental disorders. American Psychiatric Association, Arlington
  Google Scholar
• Mooijaart SP, Berbee JF, van Heemst D et al (2006) ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med 3: e176. doi:10.1371/journal.pmed.0030176
• Mulder SD, Nielsen HM, Blankenstein MA, Eikelenboom P, Veerhuis R (2014) Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro. Glia 62:493–503. doi:10.1002/glia.22619
  Article PubMed Google Scholar
• Nielsen HM, Mulder SD, Belien JA, Musters RJ, Eikelenboom P, Veerhuis R (2010) Astrocytic A beta 1-42 uptake is determined by A beta-aggregation state and the presence of amyloid-associated proteins. Glia 58:1235–1246. doi:10.1002/glia.21004
  PubMed Google Scholar
• Riddell DR, Zhou H, Atchison K et al (2008) Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci 28:11445–11453
  Article PubMed CAS Google Scholar
• Rosen C, Hansson O, Blennow K, Zetterberg H (2013) Fluid biomarkers in Alzheimer’s disease—current concepts. Mol Neurodegener 8:20. doi:10.1186/1750-1326-8-20
  Article PubMed Central PubMed CAS Google Scholar
• Sanan DA, Weisgraber KH, Russell SJ et al (1994) Apolipoprotein E associates with beta amyloid peptide of Alzheimer’s disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 94:860–869. doi:10.1172/JCI117407
  Article PubMed Central PubMed CAS Google Scholar
• Schmidt C, Becker H, Zerr I (2014) Cerebrospinal fluid apolipoprotein e concentration and severity of cognitive impairment in patients with newly diagnosed Alzheimer’s disease. Am J Alzheimers Dis Other Demen 29:54–60. doi:10.1177/1533317513505133
  Article PubMed Google Scholar
• Shinohara M, Petersen RC, Dickson DW, Bu G (2013) Brain regional correlation of amyloid-beta with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-beta accumulation. Acta Neuropathol 125:535–547. doi:10.1007/s00401-013-1086-9
  Article PubMed Central PubMed CAS Google Scholar
• Simon R, Girod M, Fonbonne C et al (2012) Total ApoE and ApoE4 isoform assays in an Alzheimer’s disease case-control study by targeted mass spectrometry (n = 669): a pilot assay for methionine-containing proteotypic peptides. Mol Cell Proteomics 11:1389–1403. doi:10.1074/mcp.M112.018861
  Article PubMed Central PubMed CAS Google Scholar
• Small BJ, Rosnick CB, Fratiglioni L, Backman L (2004) Apolipoprotein E and cognitive performance: a meta-analysis. Psychol Aging 19:592–600. doi:10.1037/0882-7974.19.4.592
  Google Scholar
• Smit M, de Knijff P, Rosseneu M et al (1988) Apolipoprotein E polymorphism in The Netherlands and its effect on plasma lipid and apolipoprotein levels. Hum Genet 80:287–292
  Article PubMed CAS Google Scholar
• Song F, Poljak A, Crawford J et al (2012) Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS ONE 7:e34078. doi:10.1371/journal.pone.0034078
  Article PubMed Central PubMed CAS Google Scholar
• Toledo JB, Da X, Weiner MW et al (2014) CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol. doi:10.1007/s00401-013-1236-0
  PubMed Central Google Scholar
• Tsuang D, Leverenz JB, Lopez OL et al (2013) APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 70:223–228. doi:10.1001/jamaneurol.2013.600
  Article PubMed Central PubMed Google Scholar
• Vance JE, Hayashi H (2010) Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim Biophys Acta 1801:806–818. doi:10.1016/j.bbalip.2010.02.007
  Article PubMed CAS Google Scholar
• Vanderstichele H, Van Kerschaver E, Hesse C et al (2000) Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7:245–258
  Article PubMed CAS Google Scholar
• Vanmechelen E, Vanderstichele H, Davidsson P et al (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285:49–52. doi:10.1016/S0304-3940(00)01036-3
  Article PubMed CAS Google Scholar
• Veerhuis R, Boshuizen RS, Familian A (2005) Amyloid associated proteins in Alzheimer’s and prion disease. Curr Drug Targets CNS Neurol Disord 4:235–248
  Article PubMed CAS Google Scholar
• Verghese PB, Castellano JM, Holtzman DM (2011) Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol 10:241–252. doi:10.1016/S1474-4422(10)70325-2
  Article PubMed Central PubMed CAS Google Scholar
• Verghese PB, Castellano JM, Garai K et al (2013) ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc Natl Acad Sci USA 110:E1807–E1816. doi:10.1073/pnas.1220484110
  Article PubMed Central PubMed Google Scholar
• Ward A, Crean S, Mercaldi CJ et al (2012) Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer’s disease: a systematic review and meta-analysis. Neuroepidemiology 38:1–17. doi:10.1159/000334607
  Article PubMed Google Scholar
• Wennstrom M, Surova Y, Hall S et al (2013) Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 8:e53250. doi:10.1371/journal.pone.0053250
  Article PubMed Central PubMed CAS Google Scholar
• Wildsmith KR, Basak JM, Patterson BW et al (2012) In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. PLoS ONE 7:e38013. doi:10.1371/journal.pone.0038013
  Article PubMed Central PubMed CAS Google Scholar
• Zlokovic BV (2013) Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol 70:440–444. doi:10.1001/jamaneurol.2013.2152
  Article PubMed Google Scholar